NHS to expand opt-out HIV and hepatitis testing
The NHS will automatically test patients for HIV, Hepatitis B and Hepatitis C unless they opt out at almost 90 Accident and Emergency (A&E) units in England, the BBC can reveal.
The government is rolling out a £27m expansion of the scheme to 30 new hospitals, saying it could lead to an extra 1,900 people receiving earlier care for HIV each year.
NHS England data showed a 40% rise in the detection of blood-borne infections after the last Conservative government began piloting the scheme in November 2023.
NHS chief executive Amanda Pritchard said the "expansion of this revolutionary opt-out testing" will lead to the early detection of "thousands more cases of HIV and Hepatitis B and C".
The announcement means the scheme will be available in nearly all areas of England.
It is designed to catch cases of blood-borne viruses in people who would not usually get tested at a sexual health clinic.
NHS England data shows opt-out testing has caught 7,300 cases of newly-diagnosed blood-borne viruses, including more than 1,000 cases of HIV, 4,600 of Hepatitis B and 1,600 of Hepatitis C.
Previously expanding the scheme to 59 hospitals led to a 43% surge in detected infections over 10 months compared to the same time period two years earlier.
HIV stands for Human Immunodeficiency Virus - the immunodeficiency is the weakening of the immune system by the virus. If untreated, it can lead to late-stage HIV or Aids, the name for a collection of illnesses caused by the virus.
Hepatitis B and Hepatitis C cause inflammation of the liver and come from viral infections, according to the NHS. Both can be contracted through blood-to-blood contact with an infected person.
Opt-out testing for blood-borne viruses has been seen by health officials and ministers as a resounding success for the NHS, which has not yet released the names of the latest hospitals added to the scheme.
The BBC understands health leaders hope to expand opt-out testing to detect more diseases in the future.
Sean Connaughton, from London, told the BBC he would "have been dead" had it not been for the opt-out testing.
He is one of the hundreds of people to discover they were living with HIV after being diagnosed through the scheme.
He attended hospital in October 2023 after suffering from seizures and losing 20kg (44lbs) through repeated sickness.
"Unless I had gone to A&E and I had done that test, my diagnosis would never have been known," Mr Connaughton said.
Without a diagnosis, doctors told him "some of the other infections I had would have gone into my spine and into my brain", he told the BBC.
"Two days prior to being admitted, I'd had a seizure in the bathroom and smashed my head into the basin and passed out, so the body was already breaking at that point.
"I wouldn't have survived, I don't think, another couple of weeks, if I hadn't been tested."
Richard Angell, the chief executive of sexual health charity the Terrence Higgins Trust, said opt-out testing was a "win-win for everyone".
"The benefit of opt-out testing is that you can get a test to people that would otherwise never come forward for a HIV test," Mr Angell said.
He added "that means a transformation for the individual" who can begin to take medication, which "means the virus is no longer attacking their immune system and they can't pass it on if they're having sex or having a baby".
Mr Angell said early testing also makes "good money sense for the NHS" as it allows early treatment, which stops HIV progressing, preventing severe illness, emergency visits and more costly treatments.
The testing forms part of a pledge by Sir Keir Starmer to eliminate new transmissions of HIV by 2030.
Earlier this week, Sir Keir became the first sitting prime minister to publicly take an HIV test.
Watch: Sir Keir Starmer becomes first PM to take HIV test
MP shares in Commons he is living with HIV
Terrence Higgins: Who's the man behind the name?
Sign up for our Politics Essential newsletter to read top political analysis, gain insight from across the UK and stay up to speed with the big moments. It'll be delivered straight to your inbox every weekday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
5 hours ago
- Chicago Tribune
Used in COVID shots, mRNA may help rid the body of HIV
The technology that powered COVID vaccines may also lead scientists to a cure for HIV. Using mRNA, Australian researchers said they were able to trick the virus to come out of hiding, a crucial step in ridding the body of it entirely. The research, published last week in Nature Communications, is still preliminary and so far has been shown to be successful only in a lab. But it suggests that mRNA has potential far beyond its use in vaccines as a means to deliver therapies against stubborn adversaries. Short for messenger RNA, mRNA is a set of instructions for a gene. In the case of COVID vaccines, the instructions were for a piece of the coronavirus. In the new study, they are for molecules key to targeting HIV. Dr. Sharon Lewin, director of the Doherty Institute at the University of Melbourne, who led the study, called mRNA a 'miraculous' tool 'to deliver things that you want into places that were not possible before.' Vaccines deploying mRNA instruct the body to produce a fragment of the virus, which then sets off the body's immune response. In the United States, the shots were initially hailed for turning back the pandemic, then viewed by some with suspicion and fear. Some officials, including Health Secretary Robert F. Kennedy Jr., have falsely said that they are highly dangerous and even deadly. Last week, the Department of Health and Human Services sought to limit the vaccine's availability to pregnant women, children and healthy younger adults. The administration also canceled a nearly $600 million contract with the drugmaker Moderna to develop an mRNA shot for humans against bird flu. 'The fear right now is not rational,' Lewin said, adding that 'mRNA vaccines have been given to millions of people around the world, so we have a very good understanding of their risks.' The new study describes the use of mRNA as a tool to flush HIV out of its hiding places. Other uses could involve providing proteins missing from those with certain diseases or correcting genetic errors. Frauke Muecksch, a virologist at Heidelberg University in Germany who was not involved in the work, called mRNA a 'promising, absolutely powerful technology.' Although most people may have only heard of mRNA's use in science during the pandemic, scientists have been working with it for more than 20 years, she said. 'I think it's not just therapeutically very powerful, but also for basic science, for research, it opens up a lot of avenues,' she added. Potent antiretroviral drugs can now control HIV, suppressing it to undetectable levels. Still, minute amounts of the virus lie dormant in so-called reservoirs, waiting for an opportunity to resurge. A cure for HIV would involve ferreting out all of this virus and destroying it, a strategy that has been called 'shock and kill.' A significant hurdle is that the virus lies dormant in a particular type of immune cell, called a resting CD4 cell. Because these cells are inactive, they tend to be unresponsive to drugs. The few drugs scientists have previously used to rouse the virus in these cells were not specific to HIV and had unwanted side effects. 'It's fair to say the field's been a little bit stuck,' said Brad Jones, a viral immunologist at Weill Cornell Medicine who was not involved in the latest research. In 2022, Jones and his colleagues found that the immune boost from the mRNA vaccines awakened latent HIV in people living with the virus. (Other research has shown that mRNA vaccines also activated dormant viruses including Epstein Barr.) 'You get just a little bit of a gentle nudge with some of these vaccines, and it's enough to coax some of these latent viruses out so they can be killed,' Jones said. Lewin and her colleagues had for years experimented with other ways to activate HIV but had no luck in resting cells. Seeing the success of the COVID vaccines, which used lipid nanoparticles — tiny spheres of fat — containing mRNA, her team tested similar particles. They used the particles to deliver two different sets of molecules: Tat, which is adept at switching HIV on, and CRISPR, a tool that can 'edit' genes. The researchers showed that in resting immune cells from people living with HIV, the approach coaxed the virus out of dormancy. 'It's very, very hard to deal with these cells, so I think this really targeting the right population of cells is what makes this paper special,' Muecksch said. It's unclear whether the new approach can successfully awaken all of the dormant HIV in the body, and what side effects it might produce. Lewin said that 'mRNA will almost certainly have some adverse effects, as every drug does, but we will investigate that systematically, as we do for any new drug.' In this case, she said, side effects may be more acceptable to people living with HIV than having to take medications for the rest of their lives. The researchers plan to test the method in HIV-infected animals next, before moving into clinical trials. This article originally appeared in The New York Times.
Yahoo
5 hours ago
- Yahoo
Women with genetic cancer risk being ‘missed' due to testing gaps
Families of some cancer patients are being denied the chance to find out about their cancer risk due to gaps in genetic testing, a new study has suggested. A lack of testing for Lynch syndrome also means some cancer patients are unaware of their risk of developing other cancers, academics said. Lynch syndrome is a rare condition which runs in families which puts people at a higher risk of developing cancers of the bowel, womb and ovaries. It is caused by a mutation in the gene that fixes mistakes in DNA when it is copied, which can lead to uncontrolled cell growth. Patients with bowel or womb cancer should have their tumours assessed for markers of Lynch syndrome, according to guidance for the NHS. If these markers are identified, patients should be referred for genetic testing so the diagnosis can be confirmed and they can get support and advice about cancer risk for themselves and their family. A new study by academics at the University of Edinburgh found not all womb cancer patients are being sent for genetic testing. Researchers examined data on 2,500 womb cancer patients across the UK and Ireland between 2022 and 2023. We have launched a Guide to #LynchSyndrome to help provide information and support to anyone who thinks they may have it, that it may run in the family, or have found out they have — The Eve Appeal (@eveappeal) February 13, 2023 They found that 91% of tumours were tested for markers of Lynch syndrome, but the test results were not routinely communicated to the wider clinical team. This means that follow-up genetic counselling and blood tests were not always arranged. Of the 181 participants eligible for genetic counselling, just under two-thirds (64%) were referred for appointments, according to the study, which has been published in the journal BMJ Oncology. Researchers said those who were referred faced long waits, resulting in high dropout rates, meaning only 48% of those eligible went on to get the test. Today's #LynchSyndromeAwarenessDay. Our policy team sat down with our supporter, Jane, to share her experience. As well as highlighting what else needs to be done to improve Lynch syndrome care. Read our blog: — Bowel Cancer UK (@bowelcanceruk) March 22, 2025 Experts from the university said gaps in testing mean some womb cancer patients with Lynch syndrome go undetected. Family members are also left vulnerable to cancer risk, unaware they may have the condition. Dr Neil Ryan, from the University of Edinburgh, who leads the UK audit and research collaborative in obstetrics and gynaecology, said: 'Despite clear guidance and excellent rates of tumour testing, too many women with Lynch syndrome are still being missed because they're not referred for definitive blood testing in a timely way. 'This not only denies them the chance to reduce their future cancer risk but also prevents their relatives from being tested and protected. 'Tumour testing is only cost-effective if it leads to diagnosis — we urgently need to make mainstream testing truly mainstream.'
Yahoo
5 hours ago
- Yahoo
Diabetes scheme reduces risk of condition by quarter
A diabetes prevention programme in Wales could reduce the risk of developing the condition by nearly a quarter, research has shown. But the all-Wales programme "doesn't currently live up to its name" as it only operates in parts of Wales, a charity said. Diabetes affects more than 220,000 people in Wales with projections it could rise by 22% over the next decade. Rachel Burr, head of Diabetes UK Cymru, said NHS costs had also risen and called for money to be invested in patients before they start to live with the condition. The Welsh government said funding has been allocated this year to make further progress in embedding delivery in core activity and rolling it out across Wales. Following a pilot in two parts of Wales, in 2022 the gradual roll out began with 35 of the 60 primary care clusters in Wales, prioritising areas in each health board with a high prevalence of type 2 diabetes. Funded by the Welsh government but provided by health boards, it has now been offered to more than 10,000 people across Wales. "So many people in Wales will not have access to this programme currently and that's an inequity – its not fair," said Ms Burr. "We want everyone to have access to the same level of support and care because diabetes is such a serious condition. "It's actually at crisis levels in Wales and continuing to rise and we need to make sure we're getting people the help they need before they develop diabetes if possible." David Weekes from Swansea has been among those to benefit from the prevention programme. The 67-year-old only discovered he was pre-diabetic when he went to the GP about an unrelated rash on his knees, and was sent to see the prevention team in Penclawdd. "We talked about my diet and exercise and I went back for a follow-up appointment this year," he said. "In that time I have lost 2st 1lb (13kg). I stopped eating as many biscuits and cakes and I now go to the gym every day. "I feel a lot better in myself for doing it and my glucose levels have come right down." Ms Weekes said while he was not unfit before, it gave him the warning "I needed". "I now cycle seven days a week, for about 15-16 miles (25km), and I do weightlifting in the gym." The scheme uses a blood test, called an HbA1c test, to identify those at increased risk of developing type 2 diabetes by measuring their average blood sugar levels. Those with levels between 42-47 millimoles per mole are classed as at increased risk and offered a 30-minute appointment with a healthcare support worker, where information and support is provided. A follow up appointment then takes place a year later. Dr Sarah Davies, a GP in Cardiff and primary care lead for diabetes in Wales, said blood tests would often identify someone is borderline for type 2 diabetes, but "until now we haven't had anywhere we can refer those individuals to get that support". "Primary care is on our knees and under-resourced across Wales. So sometimes those patients haven't received much in the way of information about pre diabetes. "That's why I so welcome this program to enable us to refer these individuals into a community service. "I'm hoping now that we've got this study that clearly demonstrates the benefits, this will support more widespread funding for this innovative program here in NHS Wales." She added that patients sometimes feel shame attached to being told they are pre-diabetic. "There's a lot of blame associated with it, which is not the case. There's many reasons why people end up living with overweight, obesity and at risk of type two diabetes, many complex environmental, genetic reasons. "So sometimes people don't want to face up to it, but actually giving one to one support via this program is a lovely way to be able to give an individualized approach." Alisha Davies, head of research and evaluation at Public Health Wales, said results have shown the programme has been been effective in "stalling and reducing progression" to diabetic blood glucose levels. She said "robust monitoring and evaluation" will help to understand its impact over time on "an important preventable disease in Wales". Staff from one primary care cluster in Swansea have also taken the screening to a local mosque to identify those who are either pre-diabetic or have undiagnosed diabetes. Dr Wynn Burke said: "Our practice population includes a significant Asian community who are known to be at higher risk of diabetes from a much younger age. "We do a lot of diabetes screening in high-risk individuals as part of our normal practice. "However, the percentage of our practice population with a diagnosis of type 2 diabetes remains below the expected ratio, therefore we sought to reach out and bridge potential health inequalities." Caroline Ashwood, an advanced nurse practitioner at SA1 Medical Centre, said around a fifth of the 140 people screened over three days so far had been identified as pre-diabetic, and three had diabetes. "Swansea Mosque is based within our (cluster area), and it is one of the largest in the UK with around 10,000 members, so this was a great opportunity to bridge health inequalities," she said. "The team at Swansea Mosque were equally proactive in working together. They set up the online booking system and supported us on the screening days we have already carried out." The Welsh government said: "We know preventative support makes a real difference in reducing the risk of people with prediabetes developing type 2 diabetes, and funding from a variety of sources has been used to develop and extend the programme. "To ensure more people across Wales can benefit from early support, funding has also been allocated this year to make further progress in embedding delivery in core activity and rolling out across Wales." There are more than 220,000 people in Wales with diabetes – predominantly with type 2 which is preventable – and the numbers have steadily risen in Wales. Projections by Public Health Wales (PHW) suggest that without intervention, by 2035 there will be a 22% rise in those numbers. The figures are higher among older people and men, though Diabetes UK Cymru said they were seeing more cases of people under 40 developing the condition. PHW research shows the cost and volume of medicines prescribed for diabetes has been steadily increasing over the last decade. The cost of medicine ingredients alone has risen 56% in the last five years and is now over £90m in Wales, partly because of the increase in the numbers of items prescribed. There were also 90,000 hospital admissions attributed to diabetes in Wales during 2021/2022. Type 2 diabetes is where the body does not produce enough insulin, or the body's cells do not react to insulin properly. Healthy eating, regular exercise and a healthy body weight reduce the risk of developing it. The condition can cause excessive thirst, tiredness and the need to go for a wee a lot. It can also lead to complications like heart disease, stroke, kidney disease, retina damage and foot problems if not managed well.
